|| Checking for direct PDF access through Ovid
Ceftibuten, an orally active third-generation cephalosporin, appears to be as effective as other commonly used antibacterials in the treatment of respiratory and urinary tract infections in children and adults.It has good activity against a variety of β-lactamase producing Gram-negative organisms and group A streptococci. However, it has little or no activity against Pseudomonas spp. and staphylococci.Ceftibuten appears to be well tolerated, being associated with a lower incidence of diarrhoea than amoxicillin/clavulanic acid.Because of the need to slow the development of antibacterial resistance, and the likely high acquisition cost of this agent, ceftibuten will probably be a second-line choice for most susceptible infections.Third-generation cephalosporins are often used parenterally in the treatment of serious infections. Whether ceftibuten would be useful in parenteral to oral stepdown therapy remains to be determined.